Search Results for "Indoleamine Dioxygenase Humoral Immunity"
Original Source: Indoleamine 2,3-dioxygenase is increased in hemodialysis patients and affects immune response to hepatitis B vaccination.
Acquired immunity is impaired in hemodialysis (HD) patients. Indoleamine 2,3-dioxygenase (IDO) is inducible by inflammation and through tryptophan depletion and generation of kynurenine pathway products suppresses adaptive immune response. In the present study plasma IDO levels were assessed in HD patients. Its effect on response to HBV vaccination program was evaluated.
Matching Channels
Varicella zoster virus (VZV) is one of eight herpes viruses known to infect humans (and other vertebrates). Varicella-zoster virus is known by many names, including: chickenpox virus, varicella viru...
Matching News
Preliminary results from Incyte’s INCB024360 Phase I trial on solid tumors
Incyte Corporation presented preliminary results today from the ongoing Phase I clinical trial for its oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB024360, at the American Society of Clinical...
Preclinical data support ongoing clinical trials testing IDO inhibitors as a treatment for cancer
Inhibitors of indoleamine 2,3-dioxygenase (IDO) are being assessed in clinical trials as a potential treatment for recurrent or refractory solid tumors. Clear genetic rationale for these trials, toget...
Preclinical data for potent IDO pathway inhibitor presented at AACR 2013 annual meeting
NewLink Genetics Corporation, a biopharmaceutical company primarily focused on discovering, developing and commercializing immunotherapeutic products in oncology, announced today that the company pres...
NewLink Genetics Corporation, a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the initiation of a double-blind, randomized, plac...
Testing IDO Inhibitors As A Treatment For Cancer: Preclinical Data Support Ongoing Clinical Trials
Inhibitors of indoleamine 2,3-dioxygenase (IDO) are being assessed in clinical trials as a potential treatment for recurrent or refractory solid tumors. Clear genetic rationale for these trials, toget...
FDA approves Biotest's BIVIGAM to treat Primary Humoral Immunodeficiency
Biotest Pharmaceuticals Corporation (BPC), a wholly owned U.S. subsidiary of Biotest AG, recently announced the U.S. Food and Drug Administration's (FDA) approval of BIVIGAM, its new intravenous immun...
Matching PubMed Articles
Acquired immunity is impaired in hemodialysis (HD) patients. Indoleamine 2,3-dioxygenase (IDO) is inducible by inflammation and through tryptophan depletion and generation of kynurenine pathway produc...
Indol-2-yl ethanones as novel indoleamine 2,3-dioxygenase (IDO) inhibitors.
Indoleamine 2,3-dioxygenase (IDO) is a heme dioxygenase which has been shown to be involved in the pathological immune escape of diseases such as cancer. The synthesis and structure-activity relations...
The indoleamine 2,3-dioxygenase (IDO) pathway controls allergy.
A series of recent studies have demonstrated that the immunoregulatory pathway of tryptophan catabolism, initiated by the enzyme indoleamine 2,3-dioxygenase (IDO), is a critical participant in allergi...
Two new merohexaprenoids, halicloic acids A (1) and B (2), have been isolated from the marine sponge Haliclona (Halichoclona) sp. collected in the Philippines. The glycolic acids 1 and 2 slowly decomp...
Indoleamine-2,3-dioxygenase (IDO) is an enzyme that catabolises tryptophan - an essential amino acid critical for T cell proliferation. Initially recognized as a first line of host defense against inf...
